Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tetramer assay

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Tetramer assay. Displaying page 1 of 1.
    EudraCT Number: 2013-004090-28 Sponsor Protocol Number: Fx-R-001-S1/B3461049 Start Date*: 2014-05-13
    Sponsor Name:Fold RX Pharmaceuticals, a Pfizer Company
    Full Title: TRANSTHYRETIN-ASSOCIATED AMYLOIDOSES OUTCOMES SURVEY (THAOS) – OPTIONAL BLOOD SAMPLE COLLECTION SUBSTUDY
    Medical condition: Transthyretin (TTR) a 127-amino acid, tetrameric protein, primarily synthesized in the liver, is a secreted protein present in the blood and cerebrospinal fluid and is a carrier of thyroxine and r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000849-50 Sponsor Protocol Number: MI-CP114 Start Date*: 2017-12-12
    Sponsor Name:MedImmune
    Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of...
    Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000228-14 Sponsor Protocol Number: LUC 05-003 Start Date*: 2006-02-21
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Immunization of disease-free melanoma patients with different HLA-A2 peptides.
    Medical condition: We want to vaccine HLA-A2 patients who had a cutaneous melanoma at the following AJCC stage T3b-T4 N0 M0, Tx N1-3 M0, Tx Nx M0. Disease-free after surgery. With no previous immunizations with the s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000686-37 Sponsor Protocol Number: 65114 Start Date*: 2019-08-16
    Sponsor Name:Leiden univerisity medical centre
    Full Title: (Methyl)prednisolone and diazoxide in type 1 diabetes at onset
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004321-25 Sponsor Protocol Number: NordDutchCML009 Start Date*: 2013-04-03
    Sponsor Name:VU University Medical Center
    Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af...
    Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:19:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA